Live Breaking News & Updates on Therapeutics Company Profile|Page 6
Stay updated with breaking news from Therapeutics company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Truist Financial reissued their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a report published on Thursday morning, Benzinga reports. They currently have a $120.00 price objective on the biotechnology company’s stock. A number of other analysts have also recently weighed in on VKTX. BTIG Research increased their price objective on […] ....
Raymond James upgraded shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) from an outperform rating to a strong-buy rating in a research note published on Thursday morning, MarketBeat.com reports. Raymond James currently has $116.00 price objective on the biotechnology company’s stock, up from their previous price objective of $115.00. VKTX has been the topic of […] ....
Truist Financial reaffirmed their buy rating on shares of CARGO Therapeutics (NASDAQ:CRGX – Free Report) in a research note released on Thursday morning, Benzinga reports. The firm currently has a $32.00 target price on the stock, down from their prior target price of $34.00. Separately, Jefferies Financial Group boosted their price objective on CARGO Therapeutics […] ....
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 0.9% during mid-day trading on Monday . The company traded as low as $55.25 and last traded at $55.74. 217,015 shares changed hands during trading, a decline of 87% from the average session volume of 1,733,235 shares. The stock had previously closed at $56.22. […] ....
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s stock price was down 0.9% on Monday . The company traded as low as $55.25 and last traded at $55.74. Approximately 217,015 shares traded hands during trading, a decline of 87% from the average daily volume of 1,733,235 shares. The stock had previously closed at $56.22. Analyst […] ....